StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Tuesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Trading Up 2.1 %

Lipocine stock opened at $4.90 on Tuesday. The company’s 50-day moving average is $5.14 and its two-hundred day moving average is $5.43. Lipocine has a 1 year low of $2.44 and a 1 year high of $11.79. The company has a market cap of $26.22 million, a PE ratio of -6.45 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Research analysts forecast that Lipocine will post -0.78 EPS for the current year.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC increased its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,697 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.